07.21.26 -- Why We Outsource: Robotics, Risk, And Reality In CGT

Enhance AAV gene therapy quality and regulatory compliance with our advanced AEX-based purification platform, achieving >90% full capsid purity — even for oversized AAV8 vectors.

Cell therapy success relies on integrated analytics, process development, quality, and manufacturing, using risk management and DoE strategies to ensure scalable, compliant, cost-effective delivery.

Effective template generation sets the tone for successful DNA and mRNA manufacturing, reducing risk and complexity early while supporting speed, consistency, and regulatory confidence across development and production workflows.

Risk analysis and lane qualification show supply chains perform consistently, meeting regulatory expectations by demonstrating control, reducing variability, and ensuring reliable delivery.

An on‑demand session showing how integrated governance and real‑time data boost visibility, collaboration, and control in outsourced gene therapy development.

Economic volatility, regulatory uncertainty, and capacity constraints pose major risks to CDMOs, threatening growth, profitability, and long-term sustainability in an increasingly competitive global market.

Discover how to transform logistical challenges into strategic advantages with flexible, forward-looking solutions designed for today’s dynamic clinical development landscape.

Gain practical insights into the manufacturing realities shaping in vivo CAR-T development and learn how leading teams are addressing the challenges of scaling both LNP and viral vector platforms."

Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.

By integrating perfusion into upstream manufacturing, see how this approach has achieved up to a fivefold increase in productivity, delivering titers that significantly exceed current industry benchmarks.

See how an iterative, risk‑based approach to Commissioning & Qualification shifts verification earlier, reduces late‑stage pressure, and supports smoother startups through operational readiness.

Downstream AAV manufacturing remains a critical bottleneck, and overcoming it requires true platforming that couples standardized processes with scalable, data-driven CMC systems.

Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.